Frontier IP Group PLC#: Initiation of Coverage

Creating Value for Growth Technology Companies

Frontier IP Group (“Frontier IP”) provides commercialisation services in return for equity in private technology companies. The Group’s equity holdings are in four high growth technology clusters comprising: artificial intelligence, robotics and big and sparse data; pathogens and cell imaging; food and agritech; and engineered particles and materials. Frontier IP’s early access to companies with leading-edge IP and the structural growth in the target clusters offers potential for strong upside. The year ending June 2020, saw Frontier IP’s portfolio value increase by 47 percent to £19.4m.   

Access to Leading Edge University IP

The Group has worked with Universities including Cambridge, Heriot-Watt Manchester, Plymouth, NOVA University Lisbon and the Portuguese Institute for Systems and Computer Engineering (INESC TEC). Frontier IP’s relationships help to secure early access to leading edge IP, such as AI in drug discovery that has led to a 2.4 percent equity holding in Oxford based Exscientia. In May 2020, Exscientia raised £46m in a Series C round. Exscientia’s AI is now deployed to help discover drugs for pharmaceutical majors including Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Roche and Sanofi.   

Strong Relationships with Industry Partners

Frontier IP works closely with Universities, Research Institutes and Academics to identify IP that can be commercialised. The Group then plays a main role in not only providing expertise and access to external funding but also commercialisation by taking a hands-on approach to commercial and technical development and by bringing in industry partners. This is key to increasing equity value. Industry partners include Bosch, whom Frontier introduced to portfolio companies Fieldwork Robotics and PulsiV Solar.


Of the 19 portfolio companies, a number are at a point of acceleration in commercial development, paving the way for a step up in valuation or a potential exit. Frontier IP has a proven record in commercialising University IP and increasing its EPS and NAV as portfolio company valuations rise. That success is seeing the Group invest in its own expansion for growth. We believe that Frontier IP represents an excellent opportunity for investors to gain exposure to early-stage technology companies, based on leading edge IP, which meets the needs and demands of international markets.

We initiate coverage with a Buy Recommendation.

Phil Smith, Equity Analyst, Technology | T: +44 (0)20 3617 5187 | E: [email protected]

VSA Capital Limited, New Liverpool House, 15-17 Eldon Street, London EC2M 7LD |

This email is intended solely for the named recipient. It may contain privileged and/or confidential information. If you are not one of the intended recipients, please notify the sender immediately, and destroy this email: any disclosure, copying to any person or any action taken or omitted to be taken in reliance on this e-mail, is prohibited and may be unlawful. Any views expressed in this message are those of the individual sender, except where specifically stated to be the view of VSA Capital Limited, its subsidiaries or associates. Whilst all efforts are made to safeguard inbound and outbound emails, VSA Capital Limited and its subsidiaries or associates cannot guarantee that attachments are virus-free or compatible with your systems and do not accept any liability in respect of viruses or computer problems experienced.

VSA Capital Limited will use your personal information to administer your account in order to provide any products and services you have requested from us. Your personal information will be kept secure and will not be shared with any other party unless you provide consent to that effect.

VSA Capital Limited is Authorised and Regulated by the Financial Conduct Authority and is a member of the London Stock Exchange.
The Company is registered in England with company number 2405923 at New Liverpool House, 15-17 Eldon Street, London EC2M 7LD.

Please consider the environment before printing this e-mail

unsubscribe from this list    update subscription preferences 

Leave A Reply

Please enter your comment!
Please enter your name here